The sogroya market research report is one of a series of new reports that provides sogroya market statistics, including sogroya industry global market size, regional shares, competitors with a sogroya market share, detailed sogroya market segments, market trends and opportunities, and any further data you may need to thrive in the sogroya industry. This sogroya market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The growth in the forecast period can be attributed to growing government initiatives, increasing trends in urban lifestyles, growing the rate of growth hormone diseases, growing healthcare awareness, and growing sectors in the pharmaceutical industry. Major trends in the forecast period include technological innovations, advancements in biotechnology and recombinant DNA technology, advancements in drug delivery systems, AI for personalized treatment, and a shift toward preventive medicine.
The rising demand for hormone replacement therapy (HRT) is expected to drive the growth of the Sogroya market in the coming years. HRT is used to replace hormones such as estrogen and progesterone, helping manage symptoms of menopause and hormonal imbalances. This demand is increasing due to the growing prevalence of hormonal imbalances, better awareness of HRT's benefits, and advancements in medical treatments that make it more accessible and effective. Sogroya is part of this trend, offering a once-weekly treatment for growth hormone deficiency, which helps restore normal hormone levels, improve physical function, and enhance the quality of life through a convenient and effective dosing regimen. In October 2023, the UK’s National Health Service reported that 11 million HRT prescriptions were issued in England during 2022-2023, marking a 47% increase from the previous year. Additionally, 2.3 million patients received HRT prescriptions, reflecting a 29% rise compared to the prior year. This growing demand for HRT is contributing to the expansion of the Sogroya market.
The rise in healthcare spending is also expected to fuel the growth of the Sogroya market. Healthcare spending refers to the funds allocated by individuals, businesses, governments, and other entities to support medical services and products. The increase in spending is driven by factors such as aging populations, the growing prevalence of chronic diseases, advances in medical technology, and higher demand for healthcare services and pharmaceuticals. This increase in healthcare expenditure supports Sogroya by funding research and development for hormone replacement therapies, improving access for patients with growth hormone deficiency, and ensuring insurance coverage for long-term management. This makes the treatment more accessible and affordable. For instance, in December 2023, the Centers for Medicare & Medicaid Services in the U.S. reported that healthcare spending in 2022 rose by 4.1%, reaching $4.5 trillion, up from a 3.2% increase in 2021. This rise in healthcare spending is helping drive the growth of the Sogroya market.
A significant trend in the Sogroya market is the focus on obtaining regulatory approvals to expand treatment options and improve accessibility. Regulatory approvals are granted by government agencies to ensure that drugs are safe, effective, and of high quality before they can be marketed. For example, in April 2023, Novo Nordisk received U.S. Food and Drug Administration (FDA) approval for Sogroya as a treatment for children aged 2.5 years and older with growth hormone deficiency, making it the first once-weekly growth hormone therapy available for both pediatric and adult patients. This treatment, which only requires a subcutaneous injection once a week, offers a more convenient alternative to daily injections. The approval was based on the phase 3 REAL4 study, which showed that Sogroya achieved similar height velocity outcomes to traditional daily somatropin. Common side effects include nasopharyngitis, headache, and reactions at the injection site.
The countries covered in the sogroya market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Sogroya (somapegsomatropin) is a long-acting growth hormone therapy used to treat adults with growth hormone deficiency (GHD). It offers the benefits of growth hormone replacement with the convenience of once-weekly injections, which helps improve patient adherence to treatment.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Sogroya include adult growth hormone deficiency and pediatric growth hormone deficiency. Adult growth hormone deficiency (AGHD) is a condition in which the body produces insufficient growth hormone after the normal growth period in childhood. Sogroya is available in subcutaneous injectable form and pre-filled syringes. It is distributed through various channels, such as retail pharmacies and online pharmacies, and is used by end users including hospitals, clinics, and ambulatory care settings.
The sogroya market consists of sales of syringes and needles, sterile wipes, alcohol swabs, and sharps containers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to growing government initiatives, increasing trends in urban lifestyles, growing the rate of growth hormone diseases, growing healthcare awareness, and growing sectors in the pharmaceutical industry. Major trends in the forecast period include technological innovations, advancements in biotechnology and recombinant DNA technology, advancements in drug delivery systems, AI for personalized treatment, and a shift toward preventive medicine.
The rising demand for hormone replacement therapy (HRT) is expected to drive the growth of the Sogroya market in the coming years. HRT is used to replace hormones such as estrogen and progesterone, helping manage symptoms of menopause and hormonal imbalances. This demand is increasing due to the growing prevalence of hormonal imbalances, better awareness of HRT's benefits, and advancements in medical treatments that make it more accessible and effective. Sogroya is part of this trend, offering a once-weekly treatment for growth hormone deficiency, which helps restore normal hormone levels, improve physical function, and enhance the quality of life through a convenient and effective dosing regimen. In October 2023, the UK’s National Health Service reported that 11 million HRT prescriptions were issued in England during 2022-2023, marking a 47% increase from the previous year. Additionally, 2.3 million patients received HRT prescriptions, reflecting a 29% rise compared to the prior year. This growing demand for HRT is contributing to the expansion of the Sogroya market.
The rise in healthcare spending is also expected to fuel the growth of the Sogroya market. Healthcare spending refers to the funds allocated by individuals, businesses, governments, and other entities to support medical services and products. The increase in spending is driven by factors such as aging populations, the growing prevalence of chronic diseases, advances in medical technology, and higher demand for healthcare services and pharmaceuticals. This increase in healthcare expenditure supports Sogroya by funding research and development for hormone replacement therapies, improving access for patients with growth hormone deficiency, and ensuring insurance coverage for long-term management. This makes the treatment more accessible and affordable. For instance, in December 2023, the Centers for Medicare & Medicaid Services in the U.S. reported that healthcare spending in 2022 rose by 4.1%, reaching $4.5 trillion, up from a 3.2% increase in 2021. This rise in healthcare spending is helping drive the growth of the Sogroya market.
A significant trend in the Sogroya market is the focus on obtaining regulatory approvals to expand treatment options and improve accessibility. Regulatory approvals are granted by government agencies to ensure that drugs are safe, effective, and of high quality before they can be marketed. For example, in April 2023, Novo Nordisk received U.S. Food and Drug Administration (FDA) approval for Sogroya as a treatment for children aged 2.5 years and older with growth hormone deficiency, making it the first once-weekly growth hormone therapy available for both pediatric and adult patients. This treatment, which only requires a subcutaneous injection once a week, offers a more convenient alternative to daily injections. The approval was based on the phase 3 REAL4 study, which showed that Sogroya achieved similar height velocity outcomes to traditional daily somatropin. Common side effects include nasopharyngitis, headache, and reactions at the injection site.
The key company operating in the sogroya market is Novo Nordisk A/S
North America was the largest region in the sogroya market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sogroya report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.The countries covered in the sogroya market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Sogroya (somapegsomatropin) is a long-acting growth hormone therapy used to treat adults with growth hormone deficiency (GHD). It offers the benefits of growth hormone replacement with the convenience of once-weekly injections, which helps improve patient adherence to treatment.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for Sogroya include adult growth hormone deficiency and pediatric growth hormone deficiency. Adult growth hormone deficiency (AGHD) is a condition in which the body produces insufficient growth hormone after the normal growth period in childhood. Sogroya is available in subcutaneous injectable form and pre-filled syringes. It is distributed through various channels, such as retail pharmacies and online pharmacies, and is used by end users including hospitals, clinics, and ambulatory care settings.
The sogroya market consists of sales of syringes and needles, sterile wipes, alcohol swabs, and sharps containers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Sogroya Market Characteristics4. Sogroya Market Trends And Strategies5. Sogroya Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Sogroya Pricing Analysis & Forecasts30. Global Sogroya Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Sogroya Market32. Recent Developments In The Sogroya Market
3. Sogroya Market Biologic Drug Characteristics
6. Global Sogroya Growth Analysis And Strategic Analysis Framework
8. Sogroya Market Segmentation
9. Global Sogroya Epidemiology Of Clinical Indications
10. Sogroya Market Regional And Country Analysis
11. Asia-Pacific Sogroya Market
12. China Sogroya Market
13. India Sogroya Market
14. Japan Sogroya Market
15. Australia Sogroya Market
16. South Korea Sogroya Market
17. Western Europe Sogroya Market
18. UK Sogroya Market
19. Germany Sogroya Market
20. France Sogroya Market
21. Eastern Europe Sogroya Market
22. North America Sogroya Market
23. USA Sogroya Market
24. Canada Sogroya Market
25. South America Sogroya Market
26. Middle East Sogroya Market
27. Africa Sogroya Market
28. Sogroya Market Competitive Landscape And Company Profiles
29. Global Sogroya Market Pipeline Analysis
33. Sogroya Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Sogroya Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on sogroya market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for sogroya ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sogroya market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Adult Growth Hormone Deficiency; Pediatric Growth Hormone Deficiency2) By Formulation: Subcutaneous Injectable; Pre-Filled Syringes
3) By Distribution Channel: Retail Pharmacies; Online Pharmacies
4) By End User: Hospital; Clinicals; Ambulatory Care
Key Companies Profiled: Novo Nordisk A/S
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Novo Nordisk A/S
